Eloxx Pharmaceuticals reports a Schedule 13G filing showing Stonepine-affiliated filers beneficially own 403,228 shares of Common Stock, equal to 9.9% of the class. The filing states the position comprises 400,000 shares and pre-funded warrants to acquire 50,000 shares, subject to a 9.99% beneficial ownership limitation. The percentage is calculated using 4,036,314 shares outstanding immediately after the offering, as reported in the issuer's June 9, 2026 prospectus. The reporting persons disclaim group membership and disavow beneficial ownership beyond their pecuniary interest; shared voting and dispositive power are reported for 403,228 shares.
Positive
None.
Negative
None.
Insights
Stonepine-affiliated entities report a 9.9% holding including prefunded warrants.
The filing lists 403,228 shares of Common Stock as beneficially owned across Stonepine entities and Jon M. Plexico, composed of 400,000 shares plus prefunded warrants for 50,000 shares subject to a 9.99% ownership cap. The calculation uses June 9, 2026 outstanding share count of 4,036,314.
Cash-flow treatment and disposition plans are not stated in the excerpt. Subsequent filings or disclosures would show if these holdings are passive or will change; timing and methods of any sales are not included here.
Shared voting/dispositive power is disclosed; reporting persons disclaim broader group ownership.
The filing shows zero sole voting or dispositive power and 403,228 shares of shared voting and dispositive power across the filer entities, with explicit disclaimers that each disclaims group membership and certain beneficial ownership definitions under Rule 13d-3.
For governance implications, note the position approaches the 10% threshold commonly used for notice but remains below the 9.99% limit tied to prefunded warrants. Any change in voting or disposition authority would require updated disclosure.
Key Figures
Beneficially owned shares:403,228 sharesReported ownership percentage:9.9%Prefunded warrants:50,000 shares+2 more
5 metrics
Beneficially owned shares403,228 sharesAmount beneficially owned reported by Stonepine entities
Reported ownership percentage9.9%Percent of class reported by the filers
Prefunded warrants50,000 sharesPre-funded warrants to acquire shares included in the position
Direct shares400,000 sharesCommon Stock component of the reported position
Shares outstanding used4,036,314 sharesOutstanding share count per prospectus used to calculate percentage (as of June 9, 2026)
Key Terms
pre-funded warrants, beneficial ownership limitation, shared dispositive power
3 terms
pre-funded warrantsfinancial
"pre-funded warrants to acquire 50,000 shares of Common Stock"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
beneficial ownership limitationregulatory
"subject to a 9.99% beneficial ownership limitation"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
shared dispositive powerregulatory
"Shared Dispositive Power 403,228.00"
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Eloxx Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
29014R301
(CUSIP Number)
06/09/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
29014R301
1
Names of Reporting Persons
Stonepine Capital Management, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
403,228.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
403,228.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
403,228.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
IA, OO
Comment for Type of Reporting Person: The securities beneficially owned by the reporting persons consist of (1) 400,000 shares of Common Stock, and (2) pre-funded warrants to acquire 50,000 shares of Common Stock, subject to a 9.99% beneficial ownership limitation. The percentage reported herein is calculated based on 4,036,314 shares of Common Stock outstanding immediately after the offering, as reported in the prospectus filed by the Issuer on June 9, 2026.
SCHEDULE 13G
CUSIP Number(s):
29014R301
1
Names of Reporting Persons
Stonepine Capital, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
403,228.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
403,228.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
403,228.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The securities beneficially owned by the reporting persons consist of (1) 400,000 shares of Common Stock, and (2) pre-funded warrants to acquire 50,000 shares of Common Stock, subject to a 9.99% beneficial ownership limitation. The percentage reported herein is calculated based on 4,036,314 shares of Common Stock outstanding immediately after the offering, as reported in the prospectus filed by the Issuer on June 9, 2026.
SCHEDULE 13G
CUSIP Number(s):
29014R301
1
Names of Reporting Persons
Stonepine GP, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
403,228.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
403,228.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
403,228.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The securities beneficially owned by the reporting persons consist of (1) 400,000 shares of Common Stock, and (2) pre-funded warrants to acquire 50,000 shares of Common Stock, subject to a 9.99% beneficial ownership limitation. The percentage reported herein is calculated based on 4,036,314 shares of Common Stock outstanding immediately after the offering, as reported in the prospectus filed by the Issuer on June 9, 2026.
SCHEDULE 13G
CUSIP Number(s):
29014R301
1
Names of Reporting Persons
Jon M. Plexico
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
403,228.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
403,228.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
403,228.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
HC, IN
Comment for Type of Reporting Person: The securities beneficially owned by the reporting persons consist of (1) 400,000 shares of Common Stock, and (2) pre-funded warrants to acquire 50,000 shares of Common Stock, subject to a 9.99% beneficial ownership limitation. The percentage reported herein is calculated based on 4,036,314 shares of Common Stock outstanding immediately after the offering, as reported in the prospectus filed by the Issuer on June 9, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Eloxx Pharmaceuticals, Inc.
(b)
Address of issuer's principal executive offices:
P.O. BOX 274, Arlington, MA 02476
Item 2.
(a)
Name of person filing:
Stonepine Capital Management, LLC, a Delaware limited liability company ("Stonepine")
Stonepine Capital, LP, a Delaware limited partnership (the "Partnership")
Stonepine GP, LLC, a Delaware limited liability company (the "General Partner")
Jon M. Plexico
Stonepine and the General Partner are the investment adviser and general partner, respectively, of the Partnership. Mr. Plexico is the control person of Stonepine and the General Partner. The reporting persons are filing this Schedule 13G jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of shares of Common Stock except to the extent of that person's pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any shares of Common Stock covered by this Schedule 13G.
(b)
Address or principal business office or, if none, residence:
2900 NW Clearwater Drive, Suite 100-11, Bend OR 97703
(c)
Citizenship:
See Item 4 of the cover sheet for each reporting person.
(d)
Title of class of securities:
Common Stock
(e)
CUSIP Number(s):
29014R301
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Stonepine: 403,228
Partnership: 403,228
General Partner: 403,228
Jon M. Plexico: 403,228
(b)
Percent of class:
Stonepine: 9.9%
Partnership: 9.9%
General Partner: 9.9%
Jon M. Plexico: 9.9%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Stonepine: 0
Partnership: 0
General Partner: 0
Jon M. Plexico: 0
(ii) Shared power to vote or to direct the vote:
Stonepine: 403,228
Partnership: 403,228
General Partner: 403,228
Jon M. Plexico: 403,228
(iii) Sole power to dispose or to direct the disposition of:
Stonepine: 0
Partnership: 0
General Partner: 0
Jon M. Plexico: 0
(iv) Shared power to dispose or to direct the disposition of:
Stonepine: 403,228
Partnership: 403,228
General Partner: 403,228
Jon M. Plexico: 403,228
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
The Partnership holds Common Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Stock.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Stonepine Capital Management, LLC
Signature:
/s/ Jon M. Plexico
Name/Title:
Managing Member
Date:
06/16/2026
Stonepine Capital, L.P.
Signature:
/s/ Jon M. Plexico
Name/Title:
Managing Member of the General Partner, Stonepine GP, LLC
Date:
06/16/2026
Stonepine GP, LLC
Signature:
/s/ Jon M. Plexico
Name/Title:
Managing Member
Date:
06/16/2026
Jon M. Plexico
Signature:
/s/ Jon M. Plexico
Name/Title:
Reporting Person
Date:
06/16/2026
Exhibit Information
EXHIBIT 99 - AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G.
What stake does Stonepine report in Eloxx Pharmaceuticals (ELOX)?
Stonepine-affiliated filers report beneficial ownership of 403,228 shares, representing 9.9% of the class based on 4,036,314 shares outstanding reported after the offering.
How is the 403,228 share position composed?
The filing states the position consists of 400,000 shares of Common Stock plus pre-funded warrants to acquire 50,000 shares, subject to a 9.99% beneficial ownership limitation.
Do the reporting persons claim sole voting or dispositive power?
No. The filing reports 0 shares with sole voting or dispositive power and 403,228 shares with shared voting and dispositive power among the reporting persons.
What outstanding share count is used to calculate the percentage?
The percentage is calculated using 4,036,314 shares outstanding immediately after the offering, as stated in the issuer's prospectus filed on June 9, 2026.
Do the filers state whether they form a group?
The reporting persons state they are filing jointly but explicitly disclaim membership in a group and disclaim beneficial ownership except to the extent of pecuniary interest.
